Cargando…
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide
BACKGROUND: Arsenic trioxide [ATO, inorganic arsenite (iAs(III)) in solution] plays an important role in the treatment of acute promyelocytic leukemia (APL). However, the long-term adverse effects (AEs) and the retention of arsenic among APL patients are rarely reported. In this study, we focused on...
Autores principales: | Zheng, Yu, Mao, Yuan-Fei, Zhao, Hui-Jin, Chen, Li, Wang, Li-Ning, Zhang, Yun-Xiang, Hu, Jiong, Li, Jun-Min, Li, Xiao-Yang, Zhu, Hong-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866431/ https://www.ncbi.nlm.nih.gov/pubmed/33549147 http://dx.doi.org/10.1186/s40164-021-00205-6 |
Ejemplares similares
-
A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia
por: Alimoghaddam, Kamran
Publicado: (2014) -
On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
por: Zhang, Peng
Publicado: (2017) -
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
por: Balasundaram, Nithya, et al.
Publicado: (2022) -
Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment
por: Chen, Baowei, et al.
Publicado: (2013) -
Treatment of Acute Promyelocytic Leukemia with Single-Agent Arsenic Trioxide
por: Mathews, Vikram, et al.
Publicado: (2011)